To evaluate the effect of a single intraoperative dose of intravitreal bevacizumab (Avastin) on surgical success following trabeculectomy with mitomycin-C (MMC) over three years.
To evaluate the effect of a single intraoperative dose of intravitreal bevacizumab (Avastin) on surgical success following trabeculectomy with mitomycin-C (MMC) over three years.
Quick Take
A single intraoperative dose of intravitreal bevacizumab (Avastin) significantly improves the three-year success rate of trabeculectomy when used as an adjunct to mitomycin-C (MMC). This long-term follow-up from the ‘Bevacizumab in Trabeculectomy Study’ confirms that the benefits of anti-VEGF modulation at the time of surgery are durable over several years.
Why It Matters
While mitomycin-C is the gold standard for inhibiting fibrosis in glaucoma filtration surgery, failure due to subconjunctival scarring remains a significant clinical challenge. These findings suggest that targeting the vascular endothelial growth factor (VEGF) pathway provides a synergistic effect that enhances bleb survival. For the clinician, this provides a validated strategy to improve long-term intraocular pressure control and potentially reduce the rate of surgical revisions in glaucoma patients.
Key Findings
Study Snapshot
Design
Long-term follow-up of a clinical study
Population
Patients undergoing trabeculectomy with mitomycin-C
Practice Implications
Glaucoma surgeons should consider incorporating a single dose of bevacizumab into their trabeculectomy protocols to enhance long-term outcomes. This approach may be especially relevant for patients at high risk for bleb failure or those where long-term IOP stability is critical to preventing advanced field loss.
Who's Affected
What's Next
Future studies may investigate whether different anti-VEGF agents or varying concentrations of mitomycin-C offer even greater synergy. Long-term monitoring of the safety profile regarding bleb morphology and infection risk will continue to be a priority for surgeons adopting this technique.
AI-generated summary — always read the original source for full context
No comments yet. Be the first to share your thoughts.